Similar articles

• The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.

  Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA. Carrier M, et al. Thromb Res. 2007;120(2):215-20. doi: 10.1016/j.thromres.2006.09.014. Epub 2006 Nov 13. Thromb Res. 2007. PMID: 17098277
• Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.

  Adiguzel C, Bansal V, Litinas E, Cunanan J, Iqbal O, Nelson K, Kannan M, Hoppensteadt D, Fareed J. Adiguzel C, et al. Clin Appl Thromb Hemost. 2009 Mar-Apr;15(2):145-51. doi: 10.1177/1076029609332802. Clin Appl Thromb Hemost. 2009. PMID: 19357103
• Prevalence of the antiheparin-platelet factor 4 antibody in hemodialysis (HD) patients and its effects upon dialysis access.

  Wallace K, Dasgupta I, Stratton J, Johnston P, Parry R. Wallace K, et al. Clin Nephrol. 2010 Nov;74(5):409-10. doi: 10.5414/cnp74409. Clin Nephrol. 2010. PMID: 20979952 No abstract available.
• A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex.

  Francis JL. Francis JL. Semin Thromb Hemost. 2004 Jun;30(3):359-68. doi: 10.1055/s-2004-831049. Semin Thromb Hemost. 2004. PMID: 15282659 Review.
• When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients.

  Chang JJ, Parikh CR. Chang JJ, et al. Semin Dial. 2006 Jul-Aug;19(4):297-304. doi: 10.1111/j.1525-139X.2006.00176.x. Semin Dial. 2006. PMID: 16893407 Review.